Yet Another Reason to Exercise: It May Make You More Creative

Neuroscientist Wendy Suzuki chats about testing out her current hypothesis.

Wendy Suzuki: One of the most fascinating things about creativity is that the most recent studies are showing that it’s not just one side of the brain or the other side of the brain that everybody will tell you. It really is the most creative people are using both sides of the brain together. So this is an important concept that the brain is subdivided into two major hemispheres. We have two of each structure. Almost all the structures of our brain are paired. So the idea is well one side of the brain is for certain things and the other side of the brain is important for other things. And the one thing we can say for sure is yes, language is on the left side of the brain. But for creativity it actually makes more sense to me that with a function so broad as that, you would benefit from having the most cross talk possible between all parts of your brain. In fact that’s exactly what the neuroscience is showing. So then once we start to understand — we’re starting to understand a little bit about the brain circuits involved in creativity, that involves a lot the prefrontal cortex as you might expect. Then the question is, well, how do I up my creativity? That’s what everybody is interested in.

Well there is exciting new evidence that one of the functions of the hippocampus, an area that we know is important for long-term memory is that it’s not only important for long-term memory, but it’s critical for the function of imagination. So people have been testing people with other people, patients with damage to the hippocampi for long periods of time. No surprise they had memory impairments. They were amnesic. But one day an experimenter back in 2007 tested amnesic patients on tasks of imagination. And she asked them can you imagine a situation that you’ve never experienced before. In this case it was imagine a tropical beach. And she compared the responses to people age matched and education matched people without hippocampal damage.

What she found was these hippocampal patients, these amnesic patients who had normal language abilities, were unable to imagine a future scenario. They could say things like well, there’s blue ocean; there might be sand. But they couldn’t elaborate at all. Whereas control patients, or control subjects were able to talk all about, you know, what the beach looked like, the buildings on the beach, the boats going past them. And this led other researchers to image the brains of subjects, normal subjects as they were remembering things. And when they remembered things the hippocampus lit up. But then they asked well imagine something new. And in that situation the hippocampus lit up again. So there’s multiple modes of evidence suggesting the hippocampus is not only involved in memory but is also important for imagination. A key component of creativity. We know that exercise stimulates what we can neurogenesis or the birth of brand-new brain cells in the hippocampus. But because of those brand new brain cells in my hippocampus I’m also enhancing my imagination. So the hypothesis that I’m working on in my lab is: Can exercise actually enhance creativity?

Neuroscientist Wendy Suzuki is hard at work in her lab experimenting with a new hypothesis: Can you stimulate creativity through exercise? She thinks so, and she's got a wide array of research backing her up.

Autonomous killer robots may have already killed on the battlefield

A brief passage from a recent UN report describes what could be the first-known case of an autonomous weapon, powered by artificial intelligence, killing in the battlefield.

STM
Politics & Current Affairs
  • Autonomous weapons have been used in war for decades, but artificial intelligence is ushering in a new category of autonomous weapons.
  • These weapons are not only capable of moving autonomously but also identifying and attacking targets on their own without oversight from a human.
  • There's currently no clear international restrictions on the use of new autonomous weapons, but some nations are calling for preemptive bans.
Keep reading Show less

Is healthy sugar possible — and would you eat it?

Israeli food-tech company DouxMatok (Hebrew for "double sweet") has created a sugary product that uses 40 percent less actual sugar yet still tastes sweet.

Photo: pixel-shot / Adobe Stock
Surprising Science
  • Consumers are fed a lot of nonsense about sugar and fad diets.
  • Our bodies must consume sugar; the question is how much and in what form.
  • Companies are trying to develop healthier sugars to combat our "sugar addiction."
Keep reading Show less

Ancient megalodon shark was even bigger than estimated, finds study

A school lesson leads to more precise measurements of the extinct megalodon shark, one of the largest fish ever.

Credit: Catmando / Adobe Stock.
Surprising Science
  • A new method estimates the ancient megalodon shark was as long as 65 feet.
  • The megalodon was one of the largest fish that ever lived.
  • The new model uses the width of shark teeth to estimate its overall size.
Keep reading Show less

Meet Dr. Jennifer Doudna: she's leading the biotech revolution

She helped create CRISPR, a gene-editing technology that is changing the way we treat genetic diseases and even how we produce food.

Courtesy of Jennifer Doudna
Technology & Innovation

This article was originally published on our sister site, Freethink.

Last year, Jennifer Doudna and Emmanuelle Charpentier became the first all-woman team to win the Nobel Prize in Chemistry for their work developing CRISPR-Cas9, the gene-editing technology. The technology was invented in 2012 — and nine years later, it's truly revolutionizing how we treat genetic diseases and even how we produce food.

CRISPR allows scientists to alter DNA by using proteins that are naturally found in bacteria. They use these proteins, called Cas9, to naturally fend off viruses, destroying the virus' DNA and cutting it out of their genes. CRISPR allows scientists to co-opt this function, redirecting the proteins toward disease-causing mutations in our DNA.

So far, gene-editing technology is showing promise in treating sickle cell disease and genetic blindness — and it could eventually be used to treat all sorts of genetic diseases, from cancer to Huntington's Disease.

The biotech revolution is just getting started — and CRISPR is leading the charge. We talked with Doudna about what we can expect from genetic engineering in the future.

This interview has been lightly edited and condensed for clarity.

Freethink: You've said that your journey to becoming a scientist had humble beginnings — in your teenage bedroom when you discovered The Double Helix by Jim Watson. Back then, there weren't a lot of women scientists — what was your breakthrough moment in realizing you could pursue this as a career?

Dr. Jennifer Doudna: There is a moment that I often think back to from high school in Hilo, Hawaii, when I first heard the word "biochemistry." A researcher from the UH Cancer Center on Oahu came and gave a talk on her work studying cancer cells.

I didn't understand much of her talk, but it still made a huge impact on me. You didn't see professional women scientists in popular culture at the time, and it really opened my eyes to new possibilities. She was very impressive.

I remember thinking right then that I wanted to do what she does, and that's what set me off on the journey that became my career in science.

Freethink: The term "CRISPR" is everywhere in the media these days but it's a really complicated tool to describe. What is the one thing that you wish people understood about CRISPR that they usually get wrong?

Dr. Jennifer Doudna: People should know that CRISPR technology has revolutionized scientific research and will make a positive difference to their lives.

Researchers are gaining incredible new understanding of the nature of disease, evolution, and are developing CRISPR-based strategies to tackle our greatest health, food, and sustainability challenges.

Freethink: You previously wrote in Wired that this year, 2021, is going to be a big year for CRISPR. What exciting new developments should we be on the lookout for?

Dr. Jennifer Doudna: Before the COVID-19 pandemic, there were multiple teams around the world, including my lab and colleagues at the Innovative Genomics Institute, working on developing CRISPR-based diagnostics.

Traits that we could select for using traditional breeding methods, that might take decades, we can now engineer precisely in a much shorter time. — DR. JENNIFER DOUDNA

When the pandemic hit, we pivoted our work to focus these tools on SARS-CoV-2. The benefit of these new diagnostics is that they're fast, cheap, can be done anywhere without the need for a lab, and they can be quickly modified to detect different pathogens. I'm excited about the future of diagnostics, and not just for pandemics.

We'll also be seeing more CRISPR applications in agriculture to help combat hunger, reduce the need for toxic pesticides and fertilizers, fight plant diseases and help crops adapt to a changing climate.

Traits that we could select for using traditional breeding methods, that might take decades, we can now engineer precisely in a much shorter time.

Freethink: Curing genetic diseases isn't a pipedream anymore, but there are still some hurdles to cross before we're able to say for certain that we can do this. What are those hurdles and how close do you think we are to crossing them?

Dr. Jennifer Doudna: There are people today, like Victoria Gray, who have been successfully treated for sickle cell disease. This is just the tip of the iceberg.

There are absolutely still many hurdles. We don't currently have ways to deliver genome-editing enzymes to all types of tissues, but delivery is a hot area of research for this very reason.

We also need to continue improving on the first wave of CRISPR therapies, as well as making them more affordable and accessible.

Freethink: Another big challenge is making this technology widely available to everyone and not just the really wealthy. You've previously said that this challenge starts with the scientists.

Dr. Jennifer Doudna: A sickle cell disease cure that is 100 percent effective but can't be accessed by most of the people in need is not really a full cure.

This is one of the insights that led me to found the Innovative Genomics Institute back in 2014. It's not enough to develop a therapy, prove that it works, and move on. You have to develop a therapy that actually meets the real-world need.

Too often, scientists don't fully incorporate issues of equity and accessibility into their research, and the incentives of the pharmaceutical industry tend to run in the opposite direction. If the world needs affordable therapy, you have to work toward that goal from the beginning.

Freethink: You've expressed some concern about the ethics of using CRISPR. Do you think there is a meaningful difference between enhancing human abilities — for example, using gene therapy to become stronger or more intelligent — versus correcting deficiencies, like Type 1 diabetes or Huntington's?

Dr. Jennifer Doudna: There is a meaningful distinction between enhancement and treatment, but that doesn't mean that the line is always clear. It isn't.

There's always a gray area when it comes to complex ethical issues like this, and our thinking on this is undoubtedly going to evolve over time.

What we need is to find an appropriate balance between preventing misuse and promoting beneficial innovation.

Freethink: What if it turns out that being physically stronger helps you live a longer life — if that's the case, are there some ways of improving health that we should simply rule out?

Dr. Jennifer Doudna: The concept of improving the "healthspan" of individuals is an area of considerable interest. Eliminating neurodegenerative disease will not only massively reduce suffering around the world, but it will also meaningfully increase the healthy years for millions of individuals.

There is a meaningful distinction between enhancement and treatment, but that doesn't mean that the line is always clear. It isn't. — DR. JENNIFER DOUDNA

There will also be knock-on effects, such as increased economic output, but also increased impact on the planet.

When you think about increasing lifespans just so certain people can live longer, then not only do those knock-on effects become more central, you also have to ask who is benefiting and who isn't? Is it possible to develop this technology so the benefits are shared equitably? Is it environmentally sustainable to go down this road?

Freethink: Where do you see it going from here?

Dr. Jennifer Doudna: The bio revolution will allow us to create breakthroughs in treating not just a few but whole classes of previously unaddressed genetic diseases.

We're also likely to see genome editing play a role not just in climate adaptation, but in climate change solutions as well. There will be challenges along the way both expected and unexpected, but also great leaps in progress and benefits that will move society forward. It's an exciting time to be a scientist.

Freethink: If you had to guess, what is the first disease you think we are most likely to cure, in the real world, with CRISPR?

Dr. Jennifer Doudna: Because of the progress that has already been made, sickle cell disease and beta-thalassemia are likely to be the first diseases with a CRISPR cure, but we're closely following the developments of other CRISPR clinical trials for types of cancer, a form of congenital blindness, chronic infection, and some rare genetic disorders.

The pace of clinical trials is picking up, and the list will be longer next year.

Quantcast